Grünenthal acquires US-based Thar Pharmaceuticals

har Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform.

With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.

T121 is a novel, Phase III-ready, composition-of-matter patented oral zoledronic acid drug product. It has received orphan drug designation by the U.S. Food and Drug Administration.

T121 complements and broadens Grünenthal's portfolio for CRPS, which includes IV neridronate that is currently in phase III clinical development.

Grünenthal will conduct clinical phase III development to demonstrate efficacy and safety of T121 for the treatment of patients with CRPS. Preclinical and pilot clinical evidence suggest that zoledronic acid could significantly reduce pain and other debilitating symptoms of CRPS.

Gabriel Baertschi, CEO of the Grünenthal Group, said: “Grünenthal is highly dedicated to improving the life of patients with pain and orphan diseases that have limited treatment options.

“As global leader in pain, we strive to develop innovative, life-changing products. This acquisition fully supports our strategy to become a leading player in CRPS (Complex Regional Pain Syndrome)."

Klaus-Dieter Langner, Chief Scientific Officer of Grünenthal, said: “We are expanding our development portfolio for treating patients with orphan, disabling diseases. For CRPS, an often debilitating, extremely painful syndrome, truly efficacious treatments are lacking today.

“With the successful development of our expanded portfolio, oral T121 and IV neridronate, Grünenthal seeks to offer CRPS patients new hope for the future. Our teams are highly motivated and will use all of their knowledge, experience and resources to bring these promising treatments to market for patients as soon as possible."

The former Thar Pharmaceuticals board chairman Lalit Chordia, said: "We are very proud of what our team of employees, advisors, partners and investors has accomplished in driving our T121 lead product from an idea to the initiation of Phase 3 development for the treatment of Complex Regional Pain Syndrome." 

Raymond K. Houck, former President and Chief Executive Officer of Thar Pharmaceuticals, added, “We believe Grünenthal is an exceptional strategic fit for Thar’s T121. Grünenthal combines world-leading knowledge and expertise in CRPS with the resources, motivation and dedication to successfully develop and commercialize our potential first-in-class, non-opioid oral treatment to improve the lives of CRPS patients.

"Grünenthal’s track record of bringing innovative pain treatments to patients around the globe underscores that we have chosen the right partner."

Locust Walk acted as lead financial advisor to Thar on this transaction. SunTrust Robinson Humphrey, Inc. served as co-financial advisor to Thar, and Goodwin Procter LLP served as its legal advisor.